SWITZERLAND – Novartis has announced that the primary endpoints of a Phase 3 trial evaluating canakinumab drug failed in its second attempt, missing targets to improve overall survival rates for…
Read MoreNovartis cancer drug falls short of primary endpoints at Phase 3 trial
